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Abstract
Objectives—Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis is a complex disease,
with much debate about the utility of systems for classification and diagnosis. We compared three
currently used classification systems in predicting disease prognosis.
Methods—Three classification systems were applied to 502 patients with biopsy proven ANCA
vasculitis: the Chapel Hill Consensus Conference (CHCC) definition with categories for
granulomatosis with polyangiitis (GPA, Wegener’s granulomatosis), microscopic polyangiitis
(MPA) and the Kidney Limited Disease (KLD); European Medicines Agency (EMA) system with
categories for GPA and MPA, and classification based on ANCA specificity (PR3 versus MPO).
Outcomes included treatment resistance, relapse, end stage kidney disease (ESKD) and death.
Proportional hazards models were compared between systems using an information-theoretic
approach to rank models by predictive fit. Hazard Ratios (HR) with 95% confidence intervals (CI)
and p-values are reported.
Results—ANCA specificity was predictive of relapse, with PR3-ANCA patients almost twice as
likely as those with MPO-ANCA to relapse (HR=1.89, 95% CI=1.33–2.69, p=0.0004), and ANCA
specificity had the best predictive model fit (Model Rank=1) compared to CHCC and EMA.
CHCC and EMA systems did not predict relapse. By ANCA specificity, categories of GPA, MPA
and KLD did not distinguish differences in probability of relapse-free survival. None of the
systems predicted treatment resistance, ESKD or death.
Conclusion—ANCA specificity independently predicts relapse among patients with ANCA
vasculitis with renal disease. Classification and diagnostic systems that incorporate ANCA
specificity, such as PR3-ANCA-MPA and MPO-ANCA-MPA, provide a more useful tool for
predicting relapse than the clinic pathologic category alone.
The name of a disease should be informative about clinical and pathologic phenotypes,
etiology and pathogenesis (when known), natural history and response to therapy. It should
permit the differentiation of similar diseases that have different outcomes. Optimally, the
name of a disease should reflect its underlying etiology. In 1994, the Chapel Hill Consensus
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Conference (CHCC) aimed to standardize nomenclature and definitions for vasculitis,
including microscopic polyangiitis, Wegener’s granulomatosis, Churg Strauss syndrome,
and polyarteritis nodosa.1 In 2007, the European Medicines Agency (EMA) classification
system2 proposed the same disease names but different definitions that refined and expanded
the 1990 American College of Rheumatology classification system.3 Since that time,
granulomatosis with polyangiitis (GPA) has been proposed as an alternative term for
Wegener’s granulomatosis, and will be used in place of Wegener’s granulomatosis for the
remainder of this article.4
The Chapel Hill nomenclature was meant to provide disease definitions. Neither the CHCC
nor EMA classification system provides diagnostic criteria for practicing physicians to
discriminate microscopic polyangiitis (MPA) from GPA. The advent of widespread anti-
neutrophil cytoplasmic antibody (ANCA) testing and accumulating evidence that ANCA
may participate in the cause of small vessel vasculitis5 have spawned the terms ANCA
associated vasculitis, ANCA vasculitis or ANCA disease as overarching terms for MPA,
GPA and Kidney Limited Disease (KLD) that aid patients and clinicians in therapeutic
decision-making. This approach has substantial value, yet may mask real differences in
disease phenotype and prognosis unless the ANCA specificity is included in the diagnosis.
We sought to evaluate the utility of three classification systems in predicting the outcomes
of treatment resistance, disease relapse, end stage kidney disease (ESKD) and death in a
cohort of ANCA vasculitis patients. The classification systems compared for this project
were a system based on the Chapel Hill Consensus Conference (CHCC) definitions,1 the
European Medicines Agency (EMA) classification system,2 and classification based on
ANCA serologic specificity. We hypothesized that ANCA specificity that is anti-proteinase
3 (PR3) antibodies (PR3-ANCA) versus anti-myeloperoxidase (MPO) antibodies (MPO-
ANCA), would provide a more useful classification system in distinguishing both clinical
phenotype and prognosis in ANCA vasculitis than the CHCC or EMA systems alone. We
also studied the added value of appending the ANCA specificity to the CHCC categories.
PATIENTS AND METHODS
Cohort Description
The inception cohort included patients diagnosed between 1985 and 2007 with biopsy-
proven ANCA vasculitis (including KLD) followed by the Glomerular Disease
Collaborative Network as previously described.6 ANCA tests were done by indirect
immunofluorescence microscopy or antigen-specific enzyme-linked immunosorbent assays
(ELISA). Patients were categorized as having cytoplasmic-ANCA (C-ANCA), PR3-ANCA,
or both and referred to collectively as PR3-ANCA, or perinuclear-ANCA (P-ANCA), MPO-
ANCA, or both and referred to as MPO-ANCA. Patients having only P-ANCA were
required to have a negative antinuclear antibody test. Patients included were diagnosed
between January 1985 and December 2007. Histological confirmation was based on a
kidney, lung or upper respiratory tract biopsy, consistent with pauci-immune small vessel
vasculitis or glomerulonephritis, with or without granulomatous inflammation. All renal
biopsies were evaluated by the University of North Carolina Nephropathology Laboratory.
A small cohort of additional patients in our population who were persistently ANCA
negative were excluded from the ANCA positive cohort and statistical modeling, but are
described as a group with respect to the three classification systems. Patients were excluded
if they had specificity for both PR3- and MPO-ANCA, were diagnosed with Churg-Strauss
Syndrome, or had overlap with any other autoimmune disorder.
Our proposed system of describing ANCA vasculitis based on PR3 and MPO specificity was
compared to two established classification systems: the CHCC1 and the EMA.2 Each patient
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was assigned a clinical phenotype for each system as well as ANCA specificity, disease
clinical manifestations, and outcomes all which were recorded from review of medical
records. The EMA system describes clinical phenotypes as GPA or MPA, with a priority
inclusion of any ENT involvement as GPA,1,2 while the CHCC classification includes these
GPA and MPA with an additional category for KLD. All patients were classified by CHCC
and EMA through discussion and a consensus decision among three investigators (RJ Falk,
S Lionaki and SL Hogan). Detailed information regarding organ involvement was recorded
by criteria described previously.6–8
Outcomes of interest included treatment resistance, time to relapse, ESKD and death, as
previously defined.6–8 In brief, treatment resistance was defined as persistence or new
appearance of any extra-renal manifestation of vasculitis despite immunosuppressive
therapy, and/or progressive decline in renal function in the setting of active urine sediment.
Relapse was defined as the reactivation of vasculitis in any system organ. Disease relapse
required initial response to treatment, so those who were treatment resistant were not
eligible to have a relapse. ESKD was defined as the chronic need for renal replacement
therapy. Death from any cause was noted. The frequency of ANCA type, ranked from
lowest to highest frequency for PR3-ANCA across clinical phenotype categories was plotted
by various organ system combinations, which were not mutually exclusive.
Statistical Methods
Univariate comparisons of the prevalence of each outcome (treatment resistance, relapse,
ESKD and death) across classification systems were first evaluated with Chi-square tests.
Kaplan-Meier estimates were used to plot the probability of relapse-free survival over time,
with log-rank tests to evaluate univariate differences in relapse-free survival by subgroups.
Receiver operating characteristic (ROC) curve analysis was used to assess prediction ability
of each model by individual classification systems, with a concordance index (C-index)
reported for each model. Classification systems with a C-index greater than 0.65, indicating
adequate model fit, where then directly compared for each outcome using an information-
theoretic approach, which is a system for comparing models using multi-model inferences
that allows direct comparison of the models of the three classification systems9,10.
This approach uses the delta of Akaike’s information criteria (AIC), Akaike weights (or
model probabilities), and evidence ratios to assess which model (and corresponding system)
best predicted each outcome.9,10 An additional bias correction term (AICc) was used instead
of AIC.10 The evidence ratio of interest was between the estimated best model (delta
AICc=0) and each compared model.10
Model averaging, which includes all information from the three classification system models
together, weighted by model fit, was used to obtain point estimates, 95% confidence
intervals (CI) and p-values for specific predictors of interest.9,10 Logistic regression models
were used to assess factors associated with treatment resistance, with odds ratios (OR) and
95% CI reported. Proportional hazard models were used to evaluate the risk in time to
relapse, ESKD and death, with Hazard Ratios (HR) and 95% CI provided.
Models were evaluated first with only the classification systems of interest, then controlling
for potential confounding factors, with the latter reported in the results. Predictors found in
previous analyses to be predictors of each outcome in a subgroup of this cohort6,11 were
evaluated in the multivariable model averaging. In addition to the classification systems,
control variables within each model-system included: for relapse, disease involvement in the
lungs and upper respiratory airways; for treatment resistance, age, race and initial treatment
(with or without cyclophosphamide); for ESKD: age, race, peak entry creatinine initial
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treatment (with or without cyclophosphamide), and vasculitis of the skin; and for death: age,
peak entry creatinine and initial treatment (with or without cyclophosphamide). Treatment
with cyclophosphamide as a first therapy regimen after diagnosis typically included
intravenous pulse (0.5 to 1 g/m2 per month) or oral (1 to 2 mg/kg per day) doses in
conjunction with oral corticosteroids and frequently methylprednisolone also. Treatment
without cyclophosphamide included initial treatment with corticosteroids alone or in
conjunction with other immunosuppressive regimens including azathioprine, mycophenolate
mofetil, and cyclosporine. Therapy was not randomly assigned. Peak serum creatinine
(reported as both µmol/L and mg/dL) was noted as the highest measure at the time of
diagnosis and prior to beginning treatment. Racial groups compared were White versus non-
White, since only 14% of the cohort was non-White. The majority of the factors have been
well described in the literature, but the control of skin involvement at onset has only been
seen in our prior evaluation of predictors where it was associated with a protective effect
against ESKD (HR=0.20, 95% CI=0.06–0.75, p= 0.02)6. ENT involvement was included in
the multivariable model as a potential predictor of relapse. As a sensitivity analysis, all
models re-evaluated MPA and KLD patients using the CHCC system grouped together.
A proportional hazards model was used to evaluate the impact of categorical subgroups
defined by ANCA specificity and CHCC definitions, controlling for lung and upper
respiratory involvement of the disease. Analyses were done using SAS v.9.2 statistical
software (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Study Cohort
Initially, 523 patients were considered for study inclusion. All patients were ANCA positive
with a biopsy proven pauci-immune small vessel vasculitis. Of those, 502 were finally
included in the study (of the 21 patients who were excluded: 9 had been reported as ANCA
positive but the actual specificity result by IFF and/or ELISA was not available, 1 for
positivity for both MPO- and PR3-ANCA specificity, 4 with Churg Strauss Syndrome, and 7
because long-term disease outcome was not available).
In addition to the 523 ANCA positive cases, we identified 12 additional patients who were
consistently ANCA negative. Those 12 cases were not considered for inclusion by study
design, as they could not be analyzed within the ANCA specificity system. However,
understanding the particular interest surrounding the clinical entity of ANCA negative
pauci-immune vasculitis, we provide a thorough description of this group included in this
manuscript’s discussion.
A detailed description of our study population (N=502) is displayed in Table 1. Kidney
involvement was present in 488 patients, with 466 confirmed by renal biopsy and 22 with
active urine sediment with or without renal insufficiency. A diagnostic kidney biopsy was
performed in 466 of 502 patients (93%), while the remaining 36 (7%) had a diagnostic
biopsy in other tissue (with 22 of 36 having an active urine sediment). Among the 466 with
a kidney biopsy, 103 (22%) also had diagnostic biopsy in one or more additional organs or
tissues. The most common sites for non-renal biopsies (N=139) included the lung (N=61),
skin (N=42), and sinuses (N=17, with an additional 17 sinus biopsies that were non-
diagnostic).
Analysis of clinical phenotype and response to therapy
Although the CHCC and EMA use identical names for disease categories, there were
substantial discrepancies in the allocation of patients into specific clinic pathologic
categories between the two systems. Sixty-four percent of cases classified as MPA using the
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CHCC system were considered GPA by the EMA algorithm. As a consequence, the EMA
system diagnosed the majority of patients (324/502=65%) as having GPA. In contrast, this
diagnosis was far less frequent within the CHCC system (117/502=23%, p<0.0001). The
difference between classification systems in GPA was predominantly due to the priority
inclusion of ENT involvement as GPA by the EMA system. Specifically, we found 185
(37%) patients having ENT involvement, with 100% classified as GPA by EMA, by
definition, and 87(47%) classified as GPA by the CHCC. Distribution of ANCA specificity
was also different between these two systems. Using the CHCC, 74% of PR3-ANCA
positive patients were diagnosed with GPA, whereas only 54% of PR3-ANCA positive
patients were diagnosed with GPA using the EMA algorithm. Using the CHCC definitions,
55% of MPO-ANCA patients were diagnosed with MPA, in contrast to only 34% of MPO-
ANCA patients who were diagnosed as MPA in the EMA system. MPO-ANCA was the
dominant serotype (81%) among patients with KLD, a category that is grouped with MPA
within the EMA system.
Treatment resistance was evaluated in 483 of 502 patients, excluding the 19 patients who
received no treatment. Relapse was evaluated in 374 patients as patients were not considered
eligible to relapse if they received no treatment (N=19) or were resistant to treatment
(N=109). ESKD was reached in 161 of the 502 patients (32%), and 139 of 502 died (27%).
A number of univariate differences in outcomes amongst the various classification systems
are displayed in Table 2. Treatment resistance was not markedly different across the CHCC
and EMA classification systems, but was more common among those with MPO-ANCA
(27%) than among those with PR3-ANCA (17%, p=0.016). Relapse was different across
CHCC classifications with those identified as GPA most likely to relapse (60%), with MPA
in the middle in terms of risk for relapse (37%), and KLD least likely to relapse (19%,
p<0.0001). Using the EMA system those with GPA were also more likely to relapse than
those with MPA, but the risk of relapse was closer; 44% versus 30%, respectively
(p=0.0071). PR3-ANCA specificity also had more relapse (51%) compared to MPO-ANCA
(29%). There were also variations in both ESKD and death within each of the three
classification systems (Table 2).
Among the twelve patients who were ANCA-negative, 9 of 12 were documented as negative
by both immunofluorescence and antigen-specific ELISA, and the other 3 by
immunofluorescence only with antigen-specificity not evaluated. According to the CHCC
definitions, 2 were classified as MPA, 7 as GPA, and 3 as KLD. By the EMA system, 4
were categorized as MPA, and 8 with GPA. Although not formally compared, these
distributions were generally similar to those seen in the overall ANCA-positive cohort. Of
note, 7 of the 12 ANCA-negative patients had disease involvement restricted to a single
organ or system, including the 3 with KLD.
Prognostic ability of classification systems for clinical outcomes
Each of the three candidate classification system models for relapse had adequate fit, with
C-statistics ranging from 0.86 to 0.89. The information-theoretic modeling approach for the
outcome of time to relapse, revealed that classification using ANCA specificity alone (PR3
versus MPO) had the best predictive model fit (Model Rank=1) among the three
classification models, with the lowest delta AICc of 0.00 and highest weight of 0.987 (Table
3.A). The other systems had weights at or approaching zero (Table 3.A) indicating they did
not provide predictive value for time to relapse. ANCA specificity was strongly predictive
of relapse, with PR3-ANCA positive patients almost twice as likely as those with MPO-
ANCA to relapse (HR=1.89, 95% CI=1.33–2.69, p=0.0004) (Table 3.A). The probability of
relapse-free survival over time by ANCA specificity displays these results graphically in
Figure 1.A. The only other predictor of relapse in the multivariable model was pulmonary
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involvement of the disease (HR=1.7, 95% CI=1.2–2.4, p=0.004). Upper respiratory disease
involvement, which has been an inconsistent predictor of relapse across cohorts6,11, did not
predict relapse in this analysis (HR=1.07, 95% CI=0.75–1.51, p=0.71). In the sensitivity
analysis, the same model averaging results were seen when MPA and KLD were grouped
together in the CHCC system, with ANCA specificity remaining the best predictive model
and PR3-ANCA and lung involvement remaining the significant predictors with similar
point estimates and confidence intervals (PR3 HR=1.88, 95% CI=1.33–2.68, p=0.0004, lung
involvement HR=1.68, 95% CI=1.18–2.40, p=0.004).
The probability of relapse-free survival over time by MPO-ANCA and PR3-ANCA within
each CHCC disease group (KLD, MPA and GPA) are shown in Figures 1.B., 1.C and 1.D.
Within each disease subgroup, there is a trend for those with PR3-ANCA to be more likely
to relapse. The statistical power of multivariable modeling was limited, but revealed a clear
trend for all three CHCC categories among PR3-ANCA patients to have similar and
consistently higher risks (HRs ranging from 2.52–3.25) than the categories among the MPO-
ANCA patients (HRs ranging from 1.0–1.62) (Table 4). Results were similar using the EMA
categories by ANCA specificity (data not shown).
Given the consistent results for ANCA specificity as a predictor of relapse, we sought to
better understand organ involvement of the disease by ANCA specificity. Categories of
organ system involvement were ranked by their prevalence of PR3-ANCA, and inversely by
MPO-ANCA (Figure 2). Patients with KLD or any form of vasculitis without radiological or
histological proof of granulomatous inflammation were more likely to have MPO-ANCA
and those with the most compelling evidence for necrotizing granulomatous inflammation
were most likely to have PR3-ANCA. For instance, the majority of patients with KLD had
MPO-ANCA (81%), while almost all patients with bone destruction or saddle nose
deformity had PR3-ANCA (94%).
Each of the three classification system models for treatment resistance, ESKD and death had
adequate fit, with C-statistics for treatment resistance 0.70 for all three models, 0.78 to 0.79
for ESKD and death, respectively. In comparing models, there were slight differences
between classification systems in the multivariable modeling for each outcome, however
none of the three classification systems were found to be better independent predictors of
these outcomes (Table 3.B). Results were similar for each of these outcomes for the
sensitivity analyses when MPA and KLD were grouped together in the CHCC system. For
the outcome of treatment resistance, treatment category and race were the only significant
predictors.
Those not treated with cyclophosphamide at initial diagnosis were twice as likely to be
resistant to therapy as those who received cyclophosphamide (HR=2.1, 95% CI=1.2–3.6,
p=0.011). Those of non-White race were also twice as likely to be treatment resistant (HR=
2.0, 95% CI=1.1–3.7, p=0.016).
For ESKD, controlling for classification systems, age, race, skin involvement, peak entry
creatinine, and treatment category, statistically significant predictors included peak entry
serum creatinine (HR=1.15 per unit increase of mg/dL, 95% CI=1.11–1.19, p<0.0001) and
non-White race (versus Whites, HR=1.7, 95% CI 1.1–2.6, p=0.018).
Evaluation of predictors for death (N=139 deaths) revealed that when controlling for
classification systems, age, ANCA specificity, peak entry creatinine, and treatment category
predictor variables included age (HR=1.05, 95% CI=1.04–1.07, p<0.00001) and peak entry
creatinine (HR=1.11 per mg/dL, 95% CI=1.06–1.16, p=0.00002). When death was censored
by the date of ESKD (N=80 deaths), there was still no predictive value from the
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classification systems. Other predictors for death had equivalent risk estimates (age and peak
entry creatinine).
DISCUSSION
We envision a classification system for ANCA vasculitis to be not only terms to label and
describe the disease, but a functional tool for the clinician to provide assistance in disease
recognition, treatment and prognosis. We focused on issues we consider critical for patient
management—the clinical phenotype and prediction of disease course.
The question of prognosis in ANCA vasculitis is critically important for clinicians. Because
the vast majority of the patients respond to standard induction treatment,12,13 the question is
how to weigh the risk of relapse against the risk of long term maintenance therapy to prevent
relapse. In this study, disease relapse was found to be independently predicted by PR3-
ANCA specificity, a finding consistent with previous studies,6,14 but not by other
classification systems. These PR3-ANCA positive patients may be the ones in whom
prolongation of immunosuppressive therapy after achievement of remission is reasonable,
although there is little direct data to support the contention that relapse can be prevented by
the use of current therapies.6,8,15–17
A wide range of vasculitic manifestations involving multiple anatomic sites and tissues was
observed, and was found to correlate strongly with ANCA specificity. The association
between PR3- or MPO-ANCA and the anatomic site of vasculitic involvement and/or the
presence of granulomatous inflammation was particularly interesting. The majority of
patients with KLD had MPO-ANCA (81%) and those with destructive lesions of the upper
airways had PR3-ANCA (94%). When vasculitis was expanded from the kidney-limited
variant to involve the gastrointestinal or respiratory tract, MPO-ANCA was less frequent,
and PR3-ANCA increased. Moreover, among 52 patients with histological proof of
granulomatous inflammation at any site in our cohort, 79% had PR3-ANCA and 21% had
MPO-ANCA. The principle that disease associated with MPO- and PR3-ANCA are
clinically distinct is essential to the categorization of ANCA small vessel vasculitis based on
antibody specificity.
Several hypotheses could explain the correlation of disease expression with ANCA serotype.
Among them, the entrance-portal and/or nature of any potential environmental “pathogen,”
including its ability to be distributed in the body could predict ANCA type. In addition, the
availability of the target antigen in the tissue or organ18 or the genetic background of any
particular individual may explain ANCA type. In this regard, it is interesting that PR3-
ANCA is predominant in northern Europe, whereas MPO-ANCA is the predominant in
Japan and China.19,20 ANCA disease associated with environmental factors, such as silica,21
microbes,22 medications,23 or concomitant disease24, usually demonstrate a predominance
of ANCA type. Various genes have been closely associated with ANCA vasculitis.25,26 If
the disease is genetically driven in a specific phenotypic direction, this might be influenced
by the ANCA specificity. However, the extent to which any gene might influence the
clinical phenotype of vasculitis, in what proportion of patients, and in any particular patient
is not known. Different pathogenic effects of autoantibodies against PR3 versus MPO could
confer different manifestations of disease.27,28 This could be explained by differences in
external or internal triggering events, differences in activation of effector cells, or
differences in innate or adaptive immune responses that are activated by PR3-ANCA versus
MPO-ANCA21,29–34.
The CHCC and EMA classification systems failed to provide a consistent ability to predict
ANCA vasculitis outcomes. This results in part from differences in disease “definitions.”
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For instance, the EMA system over-represents the diagnostic category of GPA2 because
essentially any upper respiratory involvement is considered to be in this category according
to the criteria of the American College of Rheumatology.3 Seventy eight percent of cases
classified as MPA by the CHCC system were instead classified as GPA using the EMA
system. Interestingly, distribution of the ANCA types differs significantly between the
CHCC classification and EMA systems. PR3-ANCA is predominant in patients deemed as
having GPA by the CHCC definitions, yet there is almost a 1:1 ratio for PR3- and MPO-
ANCA by the EMA model in patients with GPA. Long-standing clinical experience35–37 has
shown that most patients with ongoing active GPA have PR3-ANCA,38–40 although
sensitivity differs across studies.38–40
Patients with pauci-immune small vessel vasculitis who were ANCA negative were not
included in the statistical analyses for this study, but were described. Only 2.2% of patients
in our registry were known to be persistently negative in clinical ANCA assays. Various
proportions of patients with pauci-immune small vessel vasculitis fail to demonstrate ANCA
positivity across study-cohorts, with studies reporting 10 to 30% across all types of pauci-
immune small vessel vasculitis41, but this phenomenon is rarer in our population. Ideally,
patients should be tested for ANCA when the disease is active and prior to initiation of
therapy, to avoid the effect of immunomodulation. This becomes even more critical with the
use of interventions that eliminate antibodies, such as plasmapheresis and B cell depletion.
ANCA-negative patients in our cohort demonstrated symptoms of ANCA vasculitis
indistinguishable from those in ANCA-positive patients, as also reported by others.42
The strong predictive value of PR3-ANCA and lung involvement for relapse in this study is
consistent with previous studies.6,11,43 ENT involvement was not predictive of relapse in
this analysis. Prior analyses have shown only a weak or non-significant association with
prediction of relapse6,11.
With respect to treatment resistance, the predictors of being non-White and having induction
therapy without cyclophosphamide were in accord with the evaluation in our previous
cohort5. Other potential predictors of treatment resistance previously evaluated include
gender and age, which were not significant predictors in this evaluation, have shown
inconsistent results in previous cohorts.6,11 Older age and higher baseline creatinine as
predictors of death are consistent with a recent report that found older age and higher organ
damage, as measured by the Vasculitis Damage Index, to be predictors of death in a cohort
of 50 patients with GPA.44 Higher serum creatinine and the need for acute or chronic
dialysis have also been seen as a specific form of damage that contributes to mortality in
small vessel vasculitis.45 Evaluation of predictors of death found in other studies such as
pulmonary hemorrhage7 or adverse treatment events and level of disease activity46 were
beyond the scope of this paper.
Limitations for this study include that this is a cohort derived from a registry recruited by
nephrologists and therefore the vast majority of patients had ANCA glomerulonephritis at
presentation, alone, or in combination with other organ involvement. However, prevalence
of kidney involvement in ANCA vasculitis is reported to be as high as 75 to 90%47 and
therefore our population likely represents the majority of patients with this disease48.
Furthermore, kidney involvement renders a significant impact on patients’ quality of life, as
morbidity and mortality are dreadful, particularly for those with ESKD. Thus, studying
patients with kidney involvement is useful for any specialist confronting patients with small
vessel vasculitis. Other limitations, inherent to community-based cohort studies conducted
over a long period of time detail a lack of uniform treatment protocols and differences in
general clinical practice. Additionally, tests for ANCA have evolved with time and were not
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standardized across clinics; however, there is acceptable consistency between earlier ANCA
test methods and the commercial kits that are currently used.49
Classification systems are designed to provide a standard method of describing groups of
patients, not only to facilitate categorizing patients for clinical trials and comparing results
among trials in the medical literature, but above all to assist in patient care. Etiology, the
constellation of symptoms, and other predictors of outcome should be included in
classification systems if they facilitate patient care. Because ANCA specificity not only is
implicated in pathogenesis and correlates with clinical symptoms, but more importantly
helps predict the outcome of disease, it is appropriate to include ANCA specificity in the
diagnostic classification. This approach is feasible now that ANCA testing is widely
available and reliable. We recommend that PR3-ANCA and MPO-ANCA be used in
conjunction with the terms microscopic polyangiitis, granulomatosis with polyangiitis and
pauci-immune glomerulonephritis in categorizing patients within the spectrum of ANCA
vasculitis.
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Probability of relapse-free survival by ANCA specificity (A), and by MPO-ANCA and PR3-
ANCA positivity within classification groups of the Chapel Hill Consensus Conference
definitions: KLD = Kidney Limited Disease (B), MPA = Microscopic Polyangiitis (C), and
GPA = Granulomatosis with Polyangiitis (D).
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Frequency of PR3- and MPO-ANCA specificity by a variety of clinical phenotypes (organ
groupings are not mutually exclusive)
No Lung and No ENT: Vasculitis in any organ except the lungs and the ENT system.
Lung, no ENT: Vasculitis localized in the lungs but not in the ENT system.
Lung*: Vasculitis localized in the lungs without indicative markers (nodules, or cavities) or
histological proof (granulomas) of granulomatous inflammation.
Plus Gastrointestinal (GI): Vasculitis localized at any organ plus involvement of the
gastrointestinal tract.
Plus Skin: Vasculitis localized at any organ plus dermal involvement.
Plus Nerves: Vasculitis localized at any organ plus involvement of the nerves.
Any Lung: Any type of pulmonary vasculitis such as pulmonary hemorrhage, infiltrates,
nodules, cavities, granulomas, or respiratory arrest.
ENT, no Lung: Vasculitis localized at the ENT system but not in the lungs.
Any ENT: Any type of vasculitic manifestation of the ENT system.
Lung with nodules: Vasculitis localized at the lungs with radiographic proof of nodules.
Lung plus ENT: Any type of pulmonary vasculitis plus any type of vasculitic manifestation
of the ENT system.
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Table 1
Description of the study cohort (N=502)
Characteristic Mean (±SD) or Absolute # (%)
Follow-up time post diagnosis of ANCA-SVV(months) 40.5±44.9









Peak entry creatinine, (mg/dl) 4.6±3.6
Acute dialysis at onset 94(19%)
Initial Induction Therapy
    No treatment 19(4%)
    Corticosteroids alone 53(11%)
    Cyclophosphamide (intravenous) and prednisone 238(47%)
    Cyclophosphamide (oral) and prednisone 166(33%)
    Other immunosuppressive therapy 26(5%)
Response to Initial Induction Therapy (n=483; 19 not treated were excluded)
Treatment resistance 109 (23%)
    Complete remission (all therapy discontinued) 217 (45%)
    Remission on therapy 157 (32%)
Mean months to outcome (±SD)
    Relapse (N=147, among 374 who had a response)) 31.3±38.4
    ESKD (N=161) 39.2±40.2
    Death (total, N=139) 50.6±53.9
    Death (censored by ESKD, N=80) 52.7±62.5
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Table 2




Classification Systems (N=109/483) (N=147/374) (N=161/502) (N=139/502)
Chapel Hill Consensus Conference
    Granulomatosis with Polyangiitis (N=117) 20/117(17%) 58/97(60%) 24/117(21%) 20/117(17%)
    Microscopic Polyangiitis (N=264) 56/255(22%) 74/199(37%) 80/264(30%) 79/264(30%)
    Renal limited disease (N=121) 33/111(30%) 15/78(19%) 57/121(47%) 40/121(33%)
    P value 0.0711 <0.0001 <0.0001 0.0091
European Medicines Agency
    Granulomatosis with Polyangiitis (N=324) 68/317(22%) 110/249(44%) 92/324(28%) 84/324(26%)
    Microscopic Polyangiitis (N=178) 41/166(25%) 37/125(30%) 69/178(39%) 55/178(31%)
    P value 0.4244 0.0071 0.0214 0.2520
ANCA specificity
    MPO ANCA (N=283) 72/270(27%) 57/198(29%) 105/283(37%) 89/283(31%)
    PR3 ANCA (N=219) 37/213(17%) 90/176(51%) 56/219(26%) 50/219(23%)
    P value 0.0160 <0.0001 0.0069 0.0349
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Table 4
Multivariable Hazard Ratios for Time to Relapse by CHCC Disease Categories for MPO- and PR3- ANCA
Specificity
ANCA specificity and Disease
Definition Categories (n) Hazard Ratio (95% CI)* P-value
MPO-ANCA, KLD (56) Reference 1.0 NA
MPO-ANCA, MPA (121) 1.56 (0.70, 3.48) 0.276
MPO-ANCA, GPA (21) 1.36 (0.47, 3.90) 0.568
PR3-ANCA, KLD (20) 2.49 (0.89, 6.95) 0.081
PR3-ANCA, MPA (79) 2.45 (1.07, 5.63) 0.035
PR3-ANCA, GPA (77) 3.15 (1.34, 7.40) 0.009
*
The proportional hazards model for these results controlled for disease involvement of the lung and upper airways.
MPA = Microscopic Polyangiitis, GPA = Granulomatosis with Polyangiitis, KLD=Kidney Limited Disease
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